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Numerous new laser techniques have been introduced into clinical practice in an
attempt to reduce severe problems that are associated with transurethral resection
of the prostate (TURP). The technique of high-power (80 W) potassium-titanyl-
phosphate (KTP) laser vaporization of the prostate is rapidly gaining significance.
1-16
Strongly absorbed by hemoglobin, the 532 nm-based KTP laser energy penetrates
tissue to a depth of only 0.8 mm. Because of the limited optical penetration depth,
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Purpose: We determined the impact of prostate volume on the efficacy of the
high-power (80 W) potassium-titanyl-phosphate (KTP) photoselective laser
vaporization of the prostate in men with lower urinary tract symptoms (LUTS).
Materials and Methods: Patients were stratified into 3 groups according to
prostate volume: ‘< 40 g’ (n = 49) and ‘40-59 g’ (n = 49) and ‘≥ 60 g’ (n = 22).
Median follow-up was 9 months (range 6 to 21). Results: No differences in age
and follow-up duration were observed in the three groups. At baseline, no signi-
ficant differences were noted in the three groups in terms of the International
Prostate Symptom Score (IPSS) (21.4, 19.4 and 19.1; p = 0.412) as well as the
maximum flow rate (Qmax) (10.2, 9.2, and 8.6 mL/s; p = 0.291) and post-void
residual (PVR) (66.2, 80.4, and 71.5 mL; p = 0.856). The mean operative times
were 30.9, 46.9, and 58.6 minutes (p < 0.001) and total median energy deliveries
for each group were 62.3, 97.6, and 135.9 kJ, respectively (p < 0.001). No severe
intraoperative complication was observed. At the last follow-up, these parameters
improved significantly regardless of prostate volume, and the IPSS (11.1, 9.4, and
12.3; p = 0.286) as well as Qmax (15.9, 15.9, and 14.2 mL/s; p = 0.690) and PVR
(33.7, 28.4, and 14.2 mL; p = 0.395) were not significantly different among the
groups. Conclusion: Although a larger prostate requires more time and energy
delivery, photoselective laser vaporization of the prostate is safe and efficacious
for patients with LUTS regardless of prostate volume. 
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INTRODUCTIONa high volumetric power density inside the superficial
tissue layers is obtained and creates a very efficient vapori-
zation effect.
17,18 Recently, a new higher powered laser de-
vice, the lithium triborate laser, has been introduced. This
device offers an increased generator output power of 120
W and is thought to provide speedier tissue removal for
enhanced treatment efficacy.
19 A short-term follow-up study
suggested that 120 W PVP is safe and effective for treating
benign prostatic hyperplasia (BPH).
20 In addition, data on
holmium laser enucleation of the prostate (HoLEP) pro-
vide a high grade of scientific evidence to indicate that this
therapeutic modality is a recommended alternative to
TURP and open prostatectomy.
21 Even in the large prostate
gland, HoLEP provides a satisfactory outcome with low
morbidity.
22
For several decades, TURP has been considered to be
the gold standard for men with lower urinary tract symp-
toms (LUTS) secondary to BPH. However, TURP is asso-
ciated with intraoperative morbidity, especially bleeding
and perforation. HoLEP is a challenging technique be-
cause at least 50 patients are estimated to be needed to
complete the initial learning curve.
23 In contrast to HoLEP,
KTP laser vaporization is a technique that is relatively easy
to learn. In addition, evidence shows that KTP laser vapori-
zation has been favored over TURP due to significantly
lower intraoperative and early postoperative complication
rates.
15,24-26 In addition, vaporization of very large prostates
is feasible.
3 Thus, KTP laser vaporization would be ideal
for large glands, thus promising as the preferred prostatec-
tomy procedure for the treatment of BPH. In the present
study, we determined the impact of prostate volume on the
efficacy of the high-power KTP photoselective laser vapori-
zation of the prostate in men with LUTS secondary to BPH.  
Inclusion criteria
This study was approved by the Institutional Review Board
of the Seoul National University Hospital. Patients with
LUTS due to BPH underwent photoselective vaporization
(PVP) with an 80 W KTP laser at our institution. Inclusion
criteria were ages older than 50 years, maximum flow rate
(Qmax) < 10 mL/sec, and moderate or severe LUTS [Inter-
national Prostate Symptom Score (IPSS) > 8]. Men who
failed previous medical therapy were also included in this
study.
Participants
From September 2004 to May 2006, a total of 120 conse-
cutive patients, with 50-88 years of age (median age 69.0)
underwent high-power KTP photoselective laser vaporiza-
tion of the prostate for LUTS due to BPH. In patients with
a corresponding prostate-specific antigen (PSA) value > 4
ng/mL or digital rectal examination (DRE) suspicious of
prostate cancer, transrectal ultrasound (TRUS)-guided
prostate biopsy was performed. If biopsy results were nega-
tive for prostate cancer, the patients were included in this
study. Patients on antiplatelets or anticoagulants were ins-
tructed to withhold their medication prior to surgery. After
the surgery, they were instructed to resume their medica-
tion as soon as possible. 
Preoperative evaluation 
Preoperative evaluation included a history, physical exami-
nation including DRE, the IPSS, Qmax, post-void residual
(PVR) urine volume, serum PSA, and determination of
prostate volume and appearance by TRUS. Mean serum
PSA level and prostate volume were 3.1 ng/mL (range 0.2
to 19.0) and 46.4 mL (range 16 to 116), respectively. 
Method of treatment
The treatment was performed by an experienced single
surgeon (J.S.P.) and carried out under spinal as well as
general anesthesia depending on the clinical discretion of
the anesthesiologist. Laser vaporization was performed
with an 80 W KTP laser using a Greenlight PVP system
(Laserscope, San Jose, CA, USA). The fiber was inserted
through a 23F continuous flow cystoscope. Irrigation fluid
was normal saline at room temperature. Vaporization was
accomplished by keeping the fiber 1 to 2 mm away from
the target tissue. At the beginning, prostate vaporization
was performed from the bladder neck to the apex of the
prostate using a sweeping technique. 
Lasing time ranged from 8 to 130 minutes (median 42.5
minutes). The total applied energy ranged from 10.0 to
305.6 kJ with a median of 90.4 kJ. Once the procedure was
complete, the cystoscope was removed. A Foley catheter
was inserted in all patients and removed the next morning
within 24 hours without complications. The operative time
was measured from the time of cystoscope insertion into
the urethra to transurethral catheterization after the pro-
cedure. 
Follow-up
Follow-up examinations were carried out in our outpatient
department at 1, 3, 6 and 12 months later. The IPSS, Qmax,
PVR, and any complication were recorded at 1, 3, 5, and
12 month postoperative visits. Median follow-up was at 9
months (range 6 to 21). 
Statistical analysis
Data were presented as means ± standard errors in the
interquartile range (25th-75th percentiles) or numbers (%).
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The variables were evaluated for statistically significant
differences between the preoperative and postoperative
values using the paired t test. For statistical analysis, patients
were stratified into 3 groups according to prostate volume:
‘< 40 g’ (n= 49) and ‘40-59 g’ (n = 49) and ‘≥60 g’ (n = 22).
The one-way ANOVA test was used to determine statisti-
cal significance among the groups. We considered p < 0.05
to be statistically significant. Statistical software SPSS ver-
sion 10.0 (SPSS, Chicago, IL, USA) was adopted for stati-
stical analysis. 
Patient characteristics
Table 1 shows the patients characteristics. No differences
in age and follow-up duration were observed in the three
groups. As the prostate volume increased, transition zone
volume (TZV) (p < 0.001), transition zone index (TZI) (p
= 0.007) and serum PSA levels (p = 0.021) increased. The
mean operative times were 30.9 minutes for the ‘< 40 g’
group, 46.9 minutes for the ‘40-59 g’ group, and 58.6
minutes for the ‘≥ 60 g’ group (p < 0.001). Total median
energy delivery for each group was 62.3, 97.6, and 135.9
kJ, respectively (p< 0.001).
Baseline and post-treatment data
At baseline, no significant differences in IPSS scores and
uroflowmetry parameters were noted between the three
groups. After treatment, these parameters were also not
significantly different among the three groups. The IPSS
scores and uroflowmetry parameters improved significan-
tly regardless of prostate volume after surgery, although
the PVR in the > 60 g patient group did not significantly im-
prove. The baseline and post-treatment data in each group
are shown in Table 2.
Difference of data from baseline to post-treatment 
Table 3 shows the changes in IPSS scores and uroflow-
metry parameters that occurred between post-treatment
and baseline according to prostate volume, showing no
differences in the change of parameters among the groups. 
Intraoperative complications
There were no complications during the procedure and no
blood transfusions were required. However, the irrigation
solution was temporarily replaced and homeostasis was
achieved by electrocoagulation using a transurethral resec-
tion loop in three patients because it was difficult to achi-
eve homeostasis.
Postoperative complications
The complication rates within the observation period are
shown in Table 4. Mild hematuria was noted in 33 patients
(27.5%), but this was generally transient and clinically insi-
gnificant. Six patients (5.0%) developed retrograde ejacula-
tion. Two patients (1.7%) experienced clot retention posto-
peratively, which necessitated catheterization; the catheter
was successfully removed after 2 weeks in both patients.
Two patients (1.7%) had postoperative transient urgency,
which was resolved without medical intervention. Acute
epididymitis was seen in 2 patients (1.7%) after surgery,
and one (0.8%) had a urethral stricture. No other surgery-
related complications developed in the follow-up period. 
The new generation of high-power KTP lasers can create a
cavity almost bloodlessly, with added benefit of an easier
DISCUSSION
RESULTS
Table 1.Patient Characteristics
Prostate volume
< 40 g  40 - 59 g ≥60 g
pvalue*
No. 49 49 22
Age (yrs) 68.9 ± 1.1 (64.5, 72.0) 69.1 ± 1.0 (64.0, 75.0) 71.2 ± 1.8 (64.5, 77.3)  0.443
TPV (g) 31.3 ± 0.8 (29.0, 35.0)
� 48.6 ± 0.9 (42.5, 54.0)
� 74.8 ± 3.0 (63.5, 80.5)
§ < 0.001
TZV (g) 12.8 ± 0.9 (8.3, 15.0)
� 22.7 ± 1.2 (17.0, 29.5)
� 40.6 ± 4.5 (29.8, 43.3)
§ < 0.001
TZI (%) 40.0 ± 2.3 (28.4, 44.0)
� 46.4 ± 2.2 (35.5, 56.8)
�,� 52.9 ± 0.4 (45.1, 60.2)
� 0.007
PSA (ng/mL) 2.2 ± 0.5 (0.7, 2.2)
� 3.3 ± 0.4 (1.2, 4.8)
�,� 4.8 ± 1.1 (2.7, 4.5)
� 0.021
Operative time (min) 30.9 ± 2.4 (19.0, 37.0)
� 46.9 ± 2.7 (35.0, 56.5)
� 58.6 ± 5.5 (38.5, 75.0)
§ < 0.001
Energy used (kJ) 62.3 ± 4.8 (40.8, 76.4)
� 97.6 ± 5.3 (71.8, 114.7)
� 135.9 ± 15.2 (78.5, 209.8)
§ < 0.001
FU duration (months) 9.8 ± 0.6 (6.0, 13.0)  10.3 ± 0.6 (7.0, 13.0) 10.3 ± 0.6 (8.0, 10.0) 0.827
TPV, total prostate volume; TZV, transition zone volume; TZI, transition zone index; PSA, prostate-specific antigen; FU, follow-up.
Data presented are means ±standard errors (25th, 75th percentiles).
*one-way ANOVA test. 
�,�,§Superscript letters indicate significantly different results from each other.Ja Hyeon Ku, et al.
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learning curve. Histopathological studies after laser pros-
tatectomy have shown that there is only a very thin rim of
coagulative necrosis (1 to 2 mm), with no evidence of fib-
rosis or necrosis outside the prostate or any neurovascular
bundle damage.
17,18 In contrast to the vaporization Nd:YAG
laser-induced small (1.4 cm) cavity, which is walled by
much collagenous scar tissue, KTP laser vaporization
results in a larger (2.4 cm), practically collagen-free un-
scarred prostatic channel. These findings suggest that creat-
ing a larger cavity and generating less necrotic tissue also
reduce the duration required for postoperative urethral
catheterization. Nd:YAG laser treatment removes prostate
glandular tissue but leaves at least a portion of the stromal
component in the coagulated tissue intact, whereas KTP
laser vaporization removes both the stromal and the glan-
dular components.
17 In order to improve the speed of vapori-
zation, a quasi-continuous-wave KTP/532 laser that emits
an average power of 80 W was developed. It is postulated
Table 2.Data at Baseline and Post-Treatment  
Prostate volume
< 40 g  40 - 59 g ≥60 g
pvalue*
No. 49 49 22
IPSS total sum (baseline) 21.4 ± 1.2 (15.0, 29.0) 19.4 ± 1.2 (13.0, 26.0) 19.1 ± 2.0 (12.0, 27.5) 0.412
IPSS total sum (post-treatment) 11.1 ± 1.0 (6.5, 15.0) 9.4 ± 1.0 (4.0, 15.0) 12.3 ± 1.9 (6.0, 18.0) 0.286
pvalue
� < 0.001 < 0.001 0.002
VS score (baseline) 12.9 ± 0.8 (8.0, 18.0) 12.0 ± 0.8 (6.0, 17.0) 11.0 ± 1.3 (5.0, 17.3) 0.393
VS score (post-treatment) 4.9 ± 0.6 (1.0, 7.5) 4.0 ± 0.6 (1.0, 7.0) 6.3 ± 1.2 (3.0, 10.0) 0.170
pvalue
� < 0.001 <0 .001 0.003 
SS score (baseline) 8.6 ± 0.5 (6.0, 11.5) 7.4 ± 0.6 (4.0, 10.0) 8.2 ± 0.7 (6.0, 10.3) 0.330
SS score (post-treatment) 6.2 ± 0.5 (4.0, 9.0) 5.4 ± 0.5 (3.0, 7.0) 6.0 ± 0.9 (3.0, 9.0) 0.545
pvalue
� 0.001 0.006 0.024
QOL index score (baseline) 4.4 ± 0.1 (4.0, 5.0) 4.4 ± 0.2 (4.0, 5.0) 4.2 ± 0.3 (3.8, 5.0) 0.789
QOL index score (post-treatment) 2.6 ± 0.2 (2.0, 3.5) 2.1 ± 0.2 (1.0, 3.0) 2.5 ± 0.4 (1.0, 3.0) 0.326
pvalue
� < 0.001 < 0.001 < 0.001
Qmax (mL/s) (baseline) 10.2 ± 0.6 (7.1, 12.5) 9.2 ± 0.6 (7.0, 12.0) 8.6 ± 0.8 (6.0, 11.9) 0.291
Qmax (mL/s) (post-treatment) 15.9 ± 1.1 (11.1, 19.5) 15.9 ± 1.3 (7.9, 22.5) 14.2 ± 1.6 (8.0, 20.2) 0.690
pvalue
� < 0.001 < 0.001 0.001 
PVR (mL) (baseline) 66.2 ± 19.1 (4.0, 91.5) 80.4 ± 18.5 (20.0, 75.0) 71.5 ± 22.0 (19.3, 98.3) 0.856
PVR (mL) (post-treatment) 33.7 ± 9.1 (0.0, 32.3) 28.4 ± 6.6 (0.0, 41.5) 14.2 ± 1.6 (7.0, 76.5) 0.395
pvalue
� 0.033 0.002 0.365
IPSS, International Prostate Symptom Score; VS, voiding symptoms; SS, storage symptoms; QOL, quality of life; Qmax, maximum flow rate; PVR, post-void 
residual.
Data presented are mans ±standard errors (25th, 75th percentiles).
*one-way ANOVA test.
�Paired t test.
Table 3. Difference of Data from Post-Treatment to Baseline
Prostate volume
< 40 g  40 - 59 g ≥60 g
pvalue*
No. 49 49 22
IPSS total sum  - 10.3 ± 1.4 (- 17.0, - 4.0) - 9.7 ± 1.5 (- 18.8, - 3.5) - 6.6 ± 1.9 (- 10.0, -2.0) 0.330
VS score  - 7.9 ± 0.9 (- 13.0, - 3.5) - 7.8 ± 1.0 (- 12.8, - 3.0) - 4.5 ± 1.3 (- 3.0, - 1.0) 0.094
SS score  - 2.3 ± 0.7 (- 4.5, 0.5) - 1.9 ± 0.7 (- 5.0, 0.0) - 2.1 ± 0.9 (- 7.0, 0.0) 0.894
QOL index score  - 1.8 ± 0.2 (- 3.0, - 1.0) - 2.3 ± 0.3 (- 3.8, -1.0) 1.7 ± 0.4 (- 5.0, 0.0) 0.238
Qmax (mL/s)  6.0 ± 1.1 (2.3, 8.9) 7.4 ± 1.3 (1.3, 13.3) 6.7 ± 1.7 (1.7, 13.4) 0.721
PVR (mL)  - 33.6 ± 15.2 (- 60.0, 0.0) - 50.2 ± 15.4 (- 47.0, - 4.0) - 25.4 ± 26.3 (- 60.0, 21.0) 0.622 
IPSS, International Prostate Symptom Score; VS, voiding symptoms; SS, storage symptoms; QOL, quality of life; Qmax, maximum flow rate; PVR, post-void 
residual. 
Data presented are means ±standard errors (25th, 75th percentiles).
*one-way ANOVA test.that by providing more power, the KTP laser can quickly
and efficiently vaporize prostate adenoma. 
However, the results of laser prostatectomy with the
KTP laser are dependent directly on a number of factors,
including wavelength, power, duration and technique. In
addition, Monoski, et al.
13 recently showed that preopera-
tive urodynamic parameters could predict the outcome of
KTP laser vaporization. In their study, patients with de-
trusor overactivity had more voiding symptoms than those
without detrusor activity and were almost twice as likely to
require anticholinergics. Men without impaired detrusor
contractility had better IPSS, Qmax, and PVR urine
volumes compared to those with impaired detrusor con-
tractility. Furthermore, Te, et al.
14 demonstrated that there
was a significant difference in the efficacy of KTP laser
vaporization related to serum PSA level and total prostate
volume (TPV), although the overall results achieved with
KTP laser vaporization were very positive and lasted for 3
years.
With increasing use of medical therapy, patients are
presenting for definitive surgical therapy later and with
larger prostates. Sandhu, et al.
3 suggested that high-power
KTP laser vaporization is safe and efficacious, with dura-
ble results for men with symptomatic BPH and large-
volume prostates. In the study by Sandhu, et al.,
3 the
average TPV was found to be 101.3 g, and the resection
time 122.9 minutes. Generally, homeostasis of vaporiza-
tion is more effective than TURP, while vaporization is
more time-consuming.
27 Therefore, Te, et al.
2 demonstrated
that the amount of tissue vaporization would not exceed
0.5 g/min. In the present study, however, there was no
difference in the outcomes of KTP laser according to
prostate volume, although more time and energy delivery
were required as prostate volume increased. The present
study showed that patients with LUTS secondary to BPH
and undergoing high-power KTP laser vaporization had a
significant improvement in both symptoms and objective
variables. 
KTP laser vaporization is also suited for patients at high
risk
5,6,16 because of the lack of fluid absorption and bleeding
during the procedure. None of the patients had any signifi-
cant blood loss and required blood transfusions. 
Some limitations of our study should be mentioned. First
of all, our study was not a prospective, randomized one.
Therefore, the number of patients in each group was not
evenly distributed. Prospective randomized trials are,
therefore, required to confirm these findings. Second, the
follow-up time of our study was less than 1 year. Therefore,
there is some question as to whether our results are durable.
Additional studies with a longer follow-up period are
required to verify our findings. Third, in this study, serum
PSA and prostate volume after KTP laser vaporization
were not evaluated. Fourth, the number of patients was
small because this study was a single-center experience.
Finally, in our study, the incidence of retrograde ejaculation
after KTP laser vaporization was lower than that of other
series. As described previously,
28 our methods of evaluation
(questioning) may interfere with the accuracy of assess-
ment since only a small portion of Korean men tell their
sexual problems to a medical doctor. 
In conclusion, the present results show that high-power
KTP photoselective laser vaporization of the prostate is
safe and efficacious for patients with LUTS regardless of
prostate volume, although a larger prostate requires more
time and energy delivery. Despite these early promising
results, longer follow-up and a larger cohort of patients are
nevertheless needed to validate this technique further, since
long term data from randomized studies are still needed to
assess the results for KTP photoselective laser vaporization
of the prostate.
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